Adimmune

Adimmune, established in 1965, is a specialized manufacturer within the chemicals and pharmaceutical industry. The company maintains a unique market position as the sole influenza vaccine producer in Asia holding both EU GMP and US FDA certifications. Furthermore, Adimmune serves as the only PIC/S GMP-certified manufacturer of human vaccines in Taiwan, demonstrating rigorous adherence to international quality standards for biological production.

The company’s extensive product portfolio includes Trivalent and Tetravalent influenza vaccines, Influenza A (H1N1) virus monovalent vaccines, Japanese Encephalitis vaccines, Tetanus toxoid, and purified Tuberculin. Operating from a single facility in Taichung, Taiwan, Adimmune supports its R&D and manufacturing operations with a workforce of 500-1,000 employees. This technical infrastructure enables the firm to address complex public health requirements through advanced biopharmaceutical development and large-scale production capabilities.

Publicly traded under the ticker TWSE: 4142, Adimmune continues to expand its influence across the Asia-Pacific region. The organization leverages its specialized expertise to provide critical preventative healthcare solutions, maintaining a competitive edge through its regulatory certifications and long-standing history in the vaccine sector. Meet Adimmune's team to learn more about the leadership and technical experts driving these innovations. Adimmune remains committed to advancing human health through its specialized manufacturing processes and strategic focus on high-quality vaccine development for global and regional markets.